Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions
In this episode, 2 experts discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including the clinical impact of first-generation therapies and challenges related to resistance. They also explore emerging next-generation inhibitors and combination strategies that may expand treatment options and improve patient outcomes.
Decera Clinical Education Oncology Podcast · Luis Paz-Ares MD PhD, Christine Bestvina MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:
- Clinical outcomes and limitations of first-generation KRAS G12C inhibitors
- Key unmet needs, including primary and acquired resistance
- Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy
Presenters:
Luis Paz-Ares, MD, PhD
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Madrid, Spain
Christine Bestvina, MD
Associate Professor
University of Chicago Medicine
Division of Medicine
Section of Hematology/Oncology
University of Chicago Medicine
Chicago, Illinois
Link to full program:
https://bit.ly/4rhoUuN
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.